In contrast, relapsed AML cells with a higher ITD allelic burden are more sensitive to FLT3 inhibitors, suggesting that an ITD dominant clone is more likely to emerge at relapse (178). This evidence concerns the gene FLT3 and acute myeloid leukemia.